West Oak Capital LLC Sells 50 Shares of Danaher Co. (NYSE:DHR)

West Oak Capital LLC trimmed its position in Danaher Co. (NYSE:DHR) by 0.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,411 shares of the conglomerate’s stock after selling 50 shares during the quarter. West Oak Capital LLC’s holdings in Danaher were worth $2,390,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DHR. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the third quarter valued at about $40,000. FSA Wealth Management LLC bought a new position in shares of Danaher during the third quarter valued at approximately $50,000. Darwin Wealth Management LLC bought a new position in shares of Danaher in the 3rd quarter worth $55,000. Finally, Dunhill Financial LLC grew its position in shares of Danaher by 45.1% in the 3rd quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock worth $62,000 after buying an additional 69 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Up 2.0 %

Shares of Danaher stock opened at $239.83 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market cap of $173.22 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 4.32 and a beta of 0.83. Danaher Co. has a 52-week low of $222.53 and a 52-week high of $281.70. The stock has a 50-day simple moving average of $235.52 and a 200-day simple moving average of $253.65.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.02 EPS. On average, equities research analysts expect that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Analysts Set New Price Targets

A number of analysts recently commented on DHR shares. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. KeyCorp increased their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Guggenheim started coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Finally, Citigroup decreased their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.